90 Recd PCT/PTO 24 OCT 2000

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE ATTORNEY DOCKET NO. PATENT AND TRADEMARK OFFICE P101615-00009 (REV 5-93) DATE: October 24, 2000 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 U.S. APPLN, NO. (IE KNOWN, SEE 37 CFR 1.5) PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/US99/07016 24 April 1998 22 April 1999

TITLE OF INVENTION: PROCESS FOR PREPARING DOXORUBICIN

APPLICANT(S) FOR DO/EO/US: Augusto Inventi SOLARI, Giovanna ZANUSO, Silvia FILIPPINI, Francesca TORT, Sharee OTTEN, Anna Luisa COLOMBO, Charles R. HUTCHINSON

- 1. XX This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)
- 2. _ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
- 3. XX This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).
 - _ A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- 5 XX A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. _ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. XX has been transmitted by the International Bureau.
 - c. _ is not required, as the application was filed in the United States Receiving Office (RO/US)
- 6. _ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 - Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. _ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. _ have been transmitted by the International Bureau.
 - c. _ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. _ have not been made and will not be made.
- 8. _ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- 10. XX A copy of the Notification International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

- 11. XX An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 12. _ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. _ A FIRST preliminary amendment.
 - A SECOND or SUBSEQUENT preliminary amendment.
- 14. _ A substitute specification.

T.

n illi

- 15. _ A change of power of attorney and/or address letter.
- 16. XX Other items or information: PCT/ISA/210, PCT/IPEA/416 CHECK NO. 303/53-/ Drawings - 10 sheets

U.S. APPLN. NO. (IF KNO	J.S. APPLN. NO. (IF KNOWN, SEE 37 INTERNATIONAL APPLICATION		ATTORNEY DOCKET NO. P101615-00009		
C.F.R. 1.5009/67	R. 1.5009/673254 NO. PCT/US99/07016		DATE: October 24, 2000		
17. XX The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO			CALCULATIONS	PTO USE ONLY	
ENTER APP	PROPRIATE BASIC	FEE AMOUNT =		\$690	
Surcharge of \$130.00 for ful months from the earliest cla			_ 20 _ 30	\$00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	19 - 20 =	00	X \$ 18.00	\$00	
Independent Claims	03 - 3 =	00	X \$ 80.00	\$00	
Multiple dependent claim(s)	(if applicable)		+ \$270.00	\$00	
T	OTAL OF ABOVE	CALCULATIONS =		\$690	
Reduction by 1/2 for filing by Verified Small Entity statem Note 37 CFR 1.9, 1.27, 1.2	ent must also be file			\$00	
# 1		S	JBTOTAL =	\$690	
Processing fee of \$130.00 for furnishing the English translation later the _ 20 _ 30 _ months from the earliest claimed priority date (37 CFR 1.492(f)). +			\$00		
TOTAL NATIONAL FEE =			\$690		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			\$00		
At manager and the state of the		TOTAL FEES E	NCLOSED =	\$690	
in 1927				Amount to be refunded	\$
				Charged	\$
a. XX A check in the amount of \$690 to cover the above fees is enclosed. b Please charge my Deposit Account No. 01-2300 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. XX The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2300. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: Arent Fox Kintner Plotkin & Kahn PLLC 1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036 Telephone No. (202) 857-6000					

1.5



PRIS

09/673254 528 Rec'd PCT/PTO 24 OCT 2000

PCT/US99/07016

Process for Preparing Doxorubicin.

Field of the Invention

The present invention concerns a process for improving daunorubicin to doxorubicin conversion by means of host cells transformed with recombinant vectors comprising DNA encoding a daunorubicin C-14 hydroxylase together with genes conferring resistance to anthracycline antibiotics.

Background of the Invention

Anthracyclines of daunorubicin group such as doxorubicin, carminomycin and aclacinomycin and their synthetic analogs are among the most widely employed agents in antitumoral therapy (F. Arcamone, Doxorubicin, Academic Press New York, 1981, pp. 12; A. Grein, Process Biochem., 16:34, 1981; T. Kaneko, Chimicaoggi May 11, 1988; C. E. Myers et al., "Biochemical mechanism of tumor cell kill" in Anthracycline and Anthracenedione-Based Anti-cancer Agents (Lown, J. W., ed.) Elsevier Amsterdam, pp. 527-569, 1988; J. W. Lown, Pharmac. Ther. 60:185, 1993).

Anthracyclines of the daunorubicin group are naturally occurring compounds produced by various strains of *Streptomyces* (*S.peucetius*, *S.coeruieorubidus*, *S.galilaeus*, *S.griseus*, *S.griseoruber*, *S.insignis*, *S.viridochromogenes*, *S.bifurcus* and *S.sp.* strain C5) and by *Actinomyces carminata*. Doxorubicin is mainly produced by strains of *S. peucetius*. In particular daunorubicin and doxorubicin are synthesized in *Streptomyces peucetius* ATCC 29050 and in *S. peucetius subsp. caesius* ATCC 27952. The anthracycline doxorubicin is made by *S.peucetius* 27952 from malonic acid, propionic acid and glucose by the pathway summarized in Grein, Advan. Applied Microbiol. 32:203, 1987 and in Eckart and Wagner, J. Basic Microbiol. 28:137, 1988.

25 Aklavinone (11-deoxy-e-rhodomycinone), e-rhodomycinone, rhodomycin D, carminomycin and daunorubicin are established intermediates in this process. The final step in this pathway involves the C-14 hydroxylation of daunorubicin to doxorubicin.

Genes for daunorubicin biosynthesis have been obtained from *S.peucetius* 29050 and *S.peucetius* 27952 by cloning experiments (Stutzman-Engwall and Hutchinson, Proc.Natl.Acad.Sci.USA 86:3135,1988; Otten et al., J.Bacteriol. 172:3427,1990). The gene encoding the daunorubicin 14-hydroxylase, which converts daunorubicin to doxorubicin has been obtained from *S.peucetius* 29050 and its mutants by cloning experiments and it was overexpressed in the host cells of *Streptomyces* species and *Escherichia coli* as described in WO 96/27014, publication date

Sept.6,1996.

Two genes of the daunorubicin biosynthetic cluster, drrA and drrB, which confer doxorubicin and daunorubicin resistance to Streptomyces lividans have been cloned from S. peucetius **ATCC** 29050 strain (Guilfoile and Hutchinson. 5 Proc.Natl.Acad.Sci.USA 88:8553, 1991) (Accession Number M73758 of Genbank) and from the S.peucetius 7600 mutant (EP-0371,112-A and Colombo et al., J.Bacteriol.174:1641,1992). These genes encode two translationally coupled proteins, both of which are required for daunorubicin and doxorubicin resistance in this host. The sequence of the predicted product of one of the two genes is similar to the products of 10 other transport and resistance genes, most notably the P-glycoproteins from mammalian tumor cells. Another gene, drrC, which confers resistance to daunorubicin and doxorubicin with a strong sequence similarity to the Escherichia coli and Micrococcus luteus UvrA proteins involved in excision repair of DNA has been cloned from S.peucetius ATCC 29050 (Lomovskaya et al., J.Bacteriol.178:3238, 1996).

15 Summary of the invention

The present invention provides a process for improving daunorubicin to doxorubicin conversion in host cells by means of recombinant vectors comprising a DNA region or fragment containing the gene *dxrA* encoding daunorubicin 14-hydroxylase together with a DNA region or fragment containing one, two or three genes, selected from the group consisting of *drrA*, *drrB* and *drrC*, conferring resistance to daunorubicin and doxorubicin. The last three genes confer a high level of resistance in the host cells to doxorubicin, the product of the conversion process, making the process more efficient than the previous one obtained using host cells transformed with the recombinant vectors carrying only the DNA fragment containing the *dxrA* gene, described in WO 96/27014, even when a strong promoter is used.

The DNA of the invention comprises preferably all three of the *drrA*, *drrB* and *drrC* genes or only the two *drrA* and *drrB* genes.

The DNA may be ligated to a heterologous transcriptional control sequence in the correct fashion or cloned into a vector at the restriction site appropriately located near a transcriptional control sequence in a vector. Typically, the vector is a plasmid. The recombinant vectors may be used to transform a suitable host cell. The host may be strains of Actinomycetes that do not or do produce anthracyclines, preferably strains of *Streptomyces*.

5 Brief description of the drawings

Fig. 1 (a-c) illustrate the construction of the plasmid plS156 described in Example 1. This plasmid was constructed by insertion of the 2.9 kb fragment containing the doxA (formerly dxrA), the dnrV (formerly dnrORF10) and the C-terminal part of the dnrU (△dnrU, formerly dnrORF9) genes, obtained from the recombinant plasmid plS70 (WO 96/27014 and A. Inventi Solari et al., GMBIM '96, P58), under the control of the strong promoter ermE* (Bibb et al., Molec. Microbiol. 14:533, 1994) into the plasmid pWHM3 (Vara et al., J. Bacteriol. 171:5872, 1989).

In order to better describe the invention, we provide the SEQ.ID. No:1 of 2.867 nt consisting of the doxA, dnrV and the C-terminal part of the dnrU ($\triangle dnrU$) genes (complementary strand to the coding strand).

- Fig. 2 (a-d) illustrate the construction of the plasmid pIS284 described in Example 1. This plasmid contains the 2.9 kb fragment encompassing the *doxA*, the *dnrV* and the C-terminal part of the *dnrU* genes, obtained from the recombinant plasmid pIS70, under the control of the strong promoter *ermE** together with a DNA fragment of 2.3 Kb including the *drrA* and *drrB* resistance genes obtained from the plasmid pWHM603 (P. Guilfoile and C.R. Hutchinson, Proc. Natl. Acad. Sci. USA 88:8553, 1991) subcloned into the plasmid pWHM3.
- Fig. 3 (a-c) illustrate the construction of the plasmid pIS287 described in Example 2. Said plasmid was constructed by insertion of the 2.9 kb BamHI-HindIII fragment containing the doxA formerly, dxrA), dnrV (formerly dnr-ORF10) and the C-terminal part of the dnrU (ΔdnrU, formerly, dnr-ORF9) genes, obtained from the recombinant plasmid pIS70 (WO 96/727014), under the control of the strong promoter ermE* together with the 2.3 kb Xbal-HindIII DNA fragment containing the drrA and drrB

15

resistance genes and the 3.9 kb EcoRI-HindIII fragment containing the drrC resistance gene into the plasmid pWHM3.

The maps shown in Figs. 1,2 and 3 do not necessarily provide an exhaustive listing of all restriction sites present in the DNA fragments. However, the reported sites 5 are sufficient for an unambiguous recognition of the DNA segments.

Restriction sites abbreviations: Ap, apramycin;tsr, thiostrepton, amp, ampicillin; B, BamHI; G, Bg/II; N, NotI; K, KpnI; E, EcoRI; H, HindIII; P, PstI; S, SphI; X, XbaI, L, Bg/l; T, Sstl.

Detailed description of the invention.

The present invention provides a DNA molecule in which a DNA region or fragment containing the gene encoding a daunorubicin C-14 hydroxylase is joined to a DNA region or fragment containing one, two or three different genes selected from the group consisting of drrA, drrB, drrC genes encoding proteins conferring to the host cells resistance to daunorubicin and doxorubicin.

The DNA region containing the gene encoding a daunorubicin C-14 hydroxylase is preferably the 2.9 kb DNA region obtained from the recombinant plasmid pIS70 described in the patent WO 96/27014 by digestion with BamHI-HindIII enzymes. This fragment contains the doxA gene, encoding the C-14 hydroxylase. Daunorubicin C-14 hydroxylase converts daunorubicin to doxorubicin. The 2.9 kb DNA fragment also 20 comprises the dnrV gene between the Notl-Kpnl sites and a Notl-Sphl fragment containing the C-terminal part of the dnrU (ΔdnrU) gene.

Preferably, this 2.9 kb DNA fragment encoding a daunorubicin C-14 hydroxylase was ligated to both the 2.3 kb Xbal-HindIII DNA fragment containing the drrA and drrB resistance genes obtained from the plasmid pWHM603 and the 3.9 kb EcoRI-HindIII 25 fragment containing the drrC gene obtained from the plasmid pWHM264; in another preferred embodiment, the 2.9 kb DNA fragment is ligated to the 2.3 kb Xbal - HindIII DNA fragment only.

All the DNA molecules encoding a daunorubicin C-14 hydroxylase described in WO 96/27014 may be employed in the present invention.

In particular the DNA molecule of the present invention may comprise all of the 2.9 kb DNA fragment or only a part of the fragment, at least 1.2 kb in length corresponding to the *Kpnl-Bam*HI fragment containing the DNA molecule of *doxA*, encoding a daunorubicin C-14 hydroxylase, which converts daunorubicin to doxorubicin.

This DNA molecule consists essentially of the sequence reported in the patent application W0 96/27014, which sequence is referred to as the "*dxrA*" sequence. Also, the deduced amino acid sequence of the daunorubicin C-14 hydroxylase is shown in that patent application.

The DNA molecule of the present invention may comprise at least 2247 nt of the 2.3 kb Xbal-Hindll DNA fragment containing the *drrA* and *drrB* genes encoding proteins conferring to host cells resistance to daunorubicin and doxorubicin.

The DNA molecule of the invention may comprise all or part of the 3.9 kb EcoRI-HindIII fragment containing the *drrC* resistance gene, at least 2.5 kb in length corresponding to the *Sstl-SphI* fragment containing the DNA molecule of *drrC*, encoding a protein conferring to host cells resistance to daunorubicin and doxorubicin.

The present invention also includes DNA comprising genes conferring resistance to doxorubicin and daunorubicin having a sequence at least 80% identical to the sequences of the *drrA* and *drrB* genes (Guilfoile and Hutchinson, Proc.Natl.Acad.Sci.USA 88:8553, 1991) and or *drrC* gene (Lomovskaya et al., J.Bacteriol.178:3238, 1996).

The DNA molecule of the invention may be ligated to a heterologous transcriptional control sequence in the correct fashion or cloned into a vector at a restriction site appropriately located near a transcriptional control sequence in the vector. Preferably the transcription of the different genes may be coordinated by a common strong promoter such as *ermE**(Bibb et al., Molec. Microbiol. 14:533, 1994).

The DNA molecule of the invention may be ligated into any autonomously replicating and/or integrating agent comprising a DNA molecule to which one or more additional DNA segments can be added. Typically, however, the vector is a plasmid. A

20

preferred plasmid is the high-copy number plasmid pWHM3 or plJ702 (Katz et al., J. Gen. Microbiol. 129:2703, 1983). Other suitable plasmids are plJ680 (Hopwood et al., Genetic Manipulation of Streptomyces. A laboratory Manual, John Innes Foundation, Norwich, UK,1985) and pWHM601 (Guilfoile and Hutchinson, Proc. Natl. Acad. Sci. 5 USA 88:8553, 1991).

Any suitable technique may be used to insert the DNA into the vector. Insertion can be achieved by ligating the DNA into a linearized vector at an appropriate restriction site. For this, direct combination of sticky or blunt ends, homopolymer tailing, or the use of a linker or adapter molecule may be employed.

The recombinant vector may be used to transform a suitable host cells that do not or do produce anthracyclines.

The host cells may be ones that are daunorubicin or doxorubicin sensitive, i.e., cannot grow in the presence of a certain amount of daunorubicin or doxorubicin, or that are daunorubicin or doxorubicin resistant. In any case the resulting recombinant clones 15 obtained by transformation with the new recombinant vectors of the invention show higher level of resistance to daunorubicin and doxorubicin than the parental host. The level of doxorubicin resistance in recombinant S. lividans is much higher than the level observed in anthracycline producing strains S. peucetius ATCC 29050 and ATCC 27952.

The host may be a microorganism such as a bacterium. Strains of Actinomycetes, in particular strains of S. lividans and other strains of Streptomyces species that do not produce anthracyclines may be transformed. S. lividans TK 23 is a more suitable host in comparison to the S. peucetius dnrN mutant transformed with the recombinant plasmid pIS70 containing the dxrA gene used for daunorubicin to 25 doxorubicin bioconversion (WO 96/27014).

The recombinant vectors of the invention may also be used to transform a suitable host cell which produces daunorubicin, in order to enhance the conversion of daunorubicin to doxorubicin.

S. peucetius ATCC 29050 and ATCC27952 strains including their mutants that produce

anthracyclines may therefore be transformed. In particular *S. peucetius* strain WMH1654, a mutant strain obtained from *S.peucetius* ATCC 29050 and deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, USA, under the accession number ATCC55936 may be used.

Transformants of *Streptomyces* strains are typically obtained by protoplast transformation.

The invention includes processes for improving doxorubicin production by conversion of daunorubicin, which processes comprise a bioconversion process of added daunorubicin into doxorubicin in hosts which do not produce anthracyclines and a fermentation process for producing doxorubicin in hosts which directly produce daunorubicin.

Bioconversion process of daunorubicin to doxorubicin.

This process comprises:

- 1) culturing the recombinant host cells not producing daunorubicin transformed with the vectors of the invention to which daunorubicin is added and
- 2) isolating doxorubicin from the culture.

In this process the recombinant strain may be cultured at temperatures from 20°C to 40°C, for example from 24°C to 37°C. The daunorubicin is added to the culture medium from 24 to 96 hours of the growth phase. The culture is preferably carried out with shaking. The duration of the culture in the presence of daunorubicin may be from 12 to 72 hours. The concentration of daunorubicin in the culture may be from 20 to 1000 mcg/ml; for example from 100 to 400 mcg/ml.

Doxorubicin production by fermentation.

This process comprises:

- 25 1) culturing recombinant daunorubicin-producing host cells transformed with the vectors of the invention and
 - 2) isolating doxorubicin from the culture.

In this process the recombinant strain may be cultured at temperature from 20°C

to 40°C; for example from 26°C to 34°C. The culture is carried out with shaking. The duration of the culture may be from 72 to 168 hours.

Materials and Methods

Bacterial strains and plasmids: *E. coli* strain DH5α, which is sensitive to ampicillin and apramycin is used for subcloning DNA fragments. The host *S. lividans* TK23 was obtained from D. A. Hopwood (John Innes Institute, Norwich, United Kingdom) and the host *S. peucetius* WMH1654 is a mutant strain obtained from *S.peucetius* ATCC 29050 and has been deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, USA, under the accession number ATCC55936.

The plasmid cloning vectors are pGem-7Zf(+) and related plasmids (Promega, Madison, WI), plJ4070 (D. A. Hopwood) and the *E.coli-Streptomyces* shuttle vector pWHM3 (Vara et al., J. Bacteriol. 171:5872, 1989).

15

Media and buffer: *E. coli* strain DH5α is maintained on LB agar (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). When selecting for transformants, ampicillin or apramycin are added at concentrations of 100 micrograms/ml.

S. lividans TK23 and S. peucetius WMH1654 are maintained on R2YE (Hopwood et al., Genetic Manipulation of Streptomyces. A Laboratory Manual, John Innes Foundation, Norwich, UK, 1985) and ISP4 (Difco, Detroit, MI) agar media, respectively. When selecting for transformants, the plates are overlayed with soft agar containing thiostrepton at a concentration of 50 micrograms/ml.

25

Subcloning DNA fragments: DNA samples are digested with appropriate restriction enzymes and separated on agarose gels by standard methods (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). Agarose slices containing DNA fragments of interest are

excised from a gel and the DNA is isolated from these slices using the GENECLEAN device (Bio101, La Jolla, CA) or an equivalent. The isolated DNA fragments are subcloned using standard techniques (Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989) 5 into E. coli for routine manipulations, and E. coli-Streptomyces shuttle vectors or Streptomyces vectors for expression experiments.

Transformation of Streptomyces species and E. coli: Competent cells of E. coli are prepared by the calcium chloride method (Sambrook et al., Molecular Cloning. A 10 Laboratory Manual, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989) and transformed by standard techniques (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). S. lividans TK23 is grown in liquid R2YE medium (Hopwood et al., Genetic Manipulation of Streptomyces. A Laboratory Manual, John Innes Foundation, Norwich, UK, 1985) and harvested after 48 hr. The mycelial pellet is washed twice with 10.3% (wt/vol) sucrose solution and used to prepare protoplasts according to the method outlined in the Hopwood manual (Hopwood et al., Genetic Manipulation of Streptomyces, A Laboratory Manual, John Innes Foundation, Norwich, UK, 1985). The protoplast pellet is suspended in about 300 microlitres of P buffer (Hopwood et al., Genetic Manipulation of Streptomyces. A Laboratory Manual, John Innes Foundation, Norwich, UK, 1985) and 50 microlitres aliquot of this suspension is used for each transformation. Protoplasts are transformed with plasmid DNA according to the small scale transformation method of Hopwood et al. (Genetic Manipulation of Streptomyces. A Laboratory Manual, John Innes Foundation, Norwich, UK, 1985), Stutzman-Engwall and 25 Hutchinson (Proc. Natl. Acad. Sci. USA. 86:3135, 1988) or Otten et al. (J. Bacteriol. 172: 3427, 1990). After 17 hr of regeneration on R2YE medium at 30°C, the plates are overlayed with 200 micrograms/ml of thiostrepton and allowed to grow at 30°C until sporulated.

Evaluation of daunorubicin and doxorubicin resistance level: The level of resistance is expressed as Minimal Inhibitory Concentration (MIC) and is determined by the standard two-fold dilution method using R2YE medium. The strains are cultured in slants of R2YE medium and incubated at 28°C for 8-10 days. Recombinant strains are grown in the same medium added with 20 micrograms/ml of thiostrepton. Bacterial cultures containing approximately 10⁶⁻10⁷ viable cells/ml are prepared from cultures grown at 28°C at 280 rpm for 48 hours in Tryptic Soy Broth (Difco). The cultures are homogenized by glass beads. One loopful of the homogenized cultures is inoculated on the agar plates containing different concentrations of daunorubicin and doxorubicin from 0.39 to 800 micrograms/ml. The agar plates are incubated at 30°C for 7 days and the MICs are determined as the lowest_concentrations that prevent visible growth.

Daunorubicin to Doxorubicin bioconversion: *S. lividans* TK23 transformants harboring a plasmid of the invention are inoculated into 25 ml of liquid R2YE medium with 40 micrograms/ml of thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks and incubated on a rotary shaker at 280 rpm at 30 C°. After 2 days of growth, 2.5 ml of this culture are transferred to 25 ml of APM production medium: ((g/l) glucose (60), yeast extract (8), malt extract (20), NaCl (2), 3-(morpholino)propanesulfonic acid (MOPS sodium salt) (15), MgSO₄ .7H₂O (0.2), FeSO₄ .7H₂O (0.01), ZnSO₄.7H₂O (0.01), supplemented with 20 micrograms/ml of thiostrepton. 400 micrograms/ml of daunorubicin are added at 48 hr.of the growth phase. Cultures are grown in 300 ml Erlenmeyer flasks and incubated on a rotary shaker at 280 rpm at 30 C° for 72 hr. Each culture is acidified with 25 milligrams/ml of oxalic acid and after incubation at 30°C on a rotary shaker at 280 rpm for 30 min. is extracted with an equal volume of acetonitrile:methanol (1:1) at 30°C and 300 rpm for 2 hr. The extract is filtered and the filtrate is analyzed by reversed-phase high pressure liquid chromatography (RP-HPLC). RP-HPLC is performed by using a Vydac C₁₈ column (4.6 x 250 millimeters; 5

micrometers particle size) at a flow rate of 0.385 ml/min. Mobile phase A is 0.2% trifluoroacetic acid (TFA, from Pierce Chemical Co.) in H₂O and mobile phase B is 0.078% TFA in acetonitrile (from J.T.Baker Chemical Co.). Elution is performed with a linear gradient from 20 to 60% phase B in phase A in 33 minutes and monitored with a diode array detector set at 488 nm (bandwidth 12 micrometers). Daunorubicin and doxorubicin (10 micrograms/ml in methanol) are used as external standards to quantitate the amount of these metabolites isolated from the cultures.

Doxorubicin production: The *S. peucetius* WMH1654 mutant is transformed with a plasmid of the invention. Transformants are inoculated into 25 ml of R2YE medium supplemented with 20 micrograms/ml thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks on a rotary shaker at 280 rpm at 30°C. After 2 days of growth, 2.5 ml of this culture are transferred to 25 ml of APM medium supplemented with 20 micrograms/ml thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks on a rotary shaker at 280 rpm at 28°C for 96 - 120 hours. Each culture is acidified with 25 milligrams/ml of oxalic acid and, after 45 min. incubation at 30°C on a rotary shaker at 280 rpm, is extracted with an equal volume of acetonitrile:methanol (1:1) at 30°C and 300 rpm for 2 hr. The extract is filtered and the filtrate is analyzed by RP-HPLC following the same method used to analyze the bioconversion products.

Example 1

Example 1 (Fig. 1 (a-c) and Fig. 2 (a-d).

In order to remove a non-essential region, the plasmid pIS70 (WO96/27014) is before digested *EcoRI-HindIII* and the 3.5 kb fragment is subcloned into the same sites of the multiple cloning site sequence of the plasmid pGEM-7Zf (+) (Promega, Madison-WI USA) to obtain another *BamHI* restriction site. The new plasmid pGendoxAUV was *BamHI* digested and the fragment, now reduced to 2.9 kb, was transferred into the

plasmid plJ4070 (from the John Innes Institute, Norwich, UK) under the control of strong promoter *ermE**. This new plasmid, named p7doxAUV, was digested *BgIII* and the fragment inserted into the plasmid pWHM3 (J.Vara et al., J. Bacteriol. 171:5872-5881, 1989) to obtain the plasmid pIS156 (fig. 1c).

The 2.3 kb *Bgll* fragment containing the *drrA* and *drrB* resistance genes is transferred after blunt ending from the plasmid pWHM603 into the *Smal* site of the plasmid pBluescript II SK + (Stratagene) to obtain the plasmid pdrrAB and an *Xbal-HindIII* fragment is transferred from pdrrAB into the vector plJ4070 to obtain plS278. Afterwards, plS278 is digested with *EcoRI-Xbal* and inserted into the *EcoRI-Xbal* plasmid pWHM3 to obtain the plasmid plS281. This plasmid is digested with *Xbal* and the *Xbal* fragment of plasmid plS156 is inserted to obtain the plasmid plS284.

Example 2

15

Construction of the plasmid pIS287 (Fig.3 (a-c)): The *drrC* resistance gene contained in the plasmid pWHM264 is excised by *EcoRI-HindIII* digestion and inserted into the plasmid pIJ4070 to obtain the plasmid pIS282. From this plasmid, the *drrC* resistance gene is transferred as a *BgIII* fragment to pIS252 (this plasmid is a modified form of pWHM3 containing an extra *BgIII* site close to the *EcoRI* site) to obtain the plasmid pIS285. pIS285 is *EcoRI* digested and ligated with the 5.5 kb DNA fragment excised from plasmid pIS284 to obtain the plasmid pIS287.

Example 3

25 Resistance of the above recombinant plasmids to doxorubicin: The level of resistance to daunorubicin and doxorubicin of *S. lividans* TK23 transformed with the recombinant plasmids pIS70, pIS284 or pIS287 in comparison with *S. lividans* TK23, *S. lividans* TK23 transformed with the vector pWHM3 and the anthracycline producing *S. peucetius* ATCC 29050 and ATCC 27952 strains is determined as MICs on R2YE

medium following the procedure described in Materials and Methods. The maximum level of daunorubicin and doxorubicin resistance is obtained with the plasmid pIS287 containing the *drrA*, *drrB* and *drrC* resistance genes. The level of doxorubicin resistance was increased 64 times also with the plasmid containing only the *drrA* and *drrB*.resistance genes (Table 1).

Table 1. Resistance of recombinant strains to doxorubicin.

	Strain	MIC for doxorubicin (micrograms/ml)
	S. peucetius ATCC 29050	12.5
10	S. peucetius ATCC 27952	12.5
V	S. lividans TK23	12.5
ming grade	S. <i>lividans</i> TK23(pWHM3)	12.5
thinn wat	S. lividans TK23(pIS284)	800
is Same &	S. lividans TK23(pIS287)	>800
Ē		

Example 4

Bioconversion of added daunorubicin to doxorubicin in *S. lividans* TK23 transformed with plasmids containing the *doxA* daunorubicin C-14 hydroxylase gene together with different resistance genes: The pIS70, pIS284 or pIS287 plasmids are introduced into *S. lividans* TK23 by transformation with selection for thiostrepton resistance, according to the procedures described in the Materials and Methods section. The resulting *S. lividans* TK23(pIS70), *S. lividans* TK23(pIS284) and *S. lividans* TK23(pIS287) transformants are tested for the ability to bioconvert a high level (400 micrograms/ml) of daunorubicin to doxorubicin using the APM medium as described above. *S. lividans* TK23(pIS70) transformants can convert up to 11.5% of added daunorubicin to doxorubicin (Table 2). *S. lividans* TK23(pIS284) and *S. lividans* TK23(pIS287) transformants can convert up to 73.5% of added daunorubicin to doxorubicin (Table 2).

<u>Table 2</u>. Bioconversion of daunorubicin to doxorubicin by *S. lividans* strains.

	Strain	Anthracycline (micrograms/ml)			
		DOX	DNR	13-dihydroDNR	
5	S. lividans TK23(pIS70) (control)	46	250	70	
	S. lividans TK23(pIS284)	294	3 3	21	
	S. lividans TK23(pIS287)	288	24	35	

10 Example 5

Doxorubicin production in the *S. peucetius* WMH1654 *dnrX* mutant transformed with plasmids containing the *doxA* daunorubicin C-14 hydroxylase gene together with different resistance genes: The pIS284 and pIS287 plasmids are introduced into *S. peucetius* WMH1654 *dnrX* mutant strain by protoplasts transformation with selection for thiostrepton resistance, according to the procedures described in the Materials and Methods section. The resulting *S. peucetius* transformants are fermented and the fermentation broths analyzed according to the method previously described. *S. peucetius* WMH1654(pIS284) produced up to 81 micrograms/ml of doxorubicin and up to 18 micrograms/ml of daunorubicin after a 120 hr fermentation (Table 3). *S.peucetius* WMH1654(pIS287) produced up to 92 micrograms/ml of doxorubicin and no detectable amount of daunorubicin (Table 3).

<u>Table 3</u>. Doxorubicin production by *S. peucetius* WMH1654 *dnrX* strains.

Strain		Anthracycline	/ml)	
		DOX DNR		13-dihydroDNR
	S. peucetius WMH1654	41	35	18
5	S. peucetius WMH1654(plS284)	81	18	6
	S. peucetius WMH1654(pIS287)	92	0	0

SEQ ID.1

1 GGATCCGCAC CGGGTACACG GCACGGGACC GCCCACCGCG CGGTGCGCGG 5 51 TGGGCGGTCC CGTGCCGGTC GCGGCCGGCG GATCAGCGCA GCCAGACGGG 101 CAGTTCGGTG AGCCGCGCCG TCTGGGCCCC CTTCCGGCAC CACCGCAACT 10 151 CGTCGTACGG CACGGCCAGT CGGGCCTCGG GGAACCTGCT GCGCAGTACG 15 201 CCGATCATCG TGCGCGACTC CAGCTGGGCG AGCTGCTCCC CGATGCAGTA 251 GTGCGGCCG TCGCCGAAGG TGAGCCGCCG CCACGAGGGA CGGTCCGGGT 20 301 GGAAGGCGTG CGGGGCGTCG TGATGGCGGC CGTCGGTGTT GGTGCCCTCG 351 ATGTCCACCA GCACCGGCGC TCCGCGGGGC AGCCGGACGC CGCCGATGGT 401 CACCTCCGTG GCAGCGAACC TCCACAACGT GTAGGGCACC GGCGGGTGGT 451 AGCGCAGCGC CTCCTCCACG AACCGGGAGA CGGCGTCCTC GTCGGCATCC 501 GCCGCGAGGC GGCCCGCCAG GACCTCCGCG AGCAGGAAGC CCAGGAAGGA 35 551 GCCGGTGGTG TCGTGGCCGG CGAAGATGAG CCCGGTGATC ATGTAGACGA 40 601 GCTGGTCGTC GGAGACCGAG CCGAACTCGG CCTGCGCGCG CTCGTACAGC 651 ACGCGGGTCA TGGTCGGGGT GTCGTTCCGC CGGGCTGAGT GCACGGCTTC 45 701 GAGGAGCAGG CTCTCCAGGG CCGAGGTGTC CGGCACGCCC CCGGCAGGGT 751 CCGTGCCGTC ACCCCGCCG CTCTGCGGGC CGCCGAGGCC GAGTGCCTTG 50 801 AGAACGCTGA CGGCCTCGCG GGCCATCGCC GGATCGGTGA CCGGCACACC

40

45

50

5

10

15

851 GAGCAGCTCG CAGATGACCA ACAGCGGGAA GTGGTACGCG AAGCCGCCGA 901 TCAGCTCGGC CGGTTTGCCC GACCGGCCGG AGGCGTCGGC GAGTTCGGTG 951 AGCAGCCGGC CGGCGATCGC GGCGATGCGA TCCGTCCGCT CGGCCAGCCG 1001 GCGCGGTTG AACGCAGGTG CGTGGATGCG GCGCAGGCGC CGGTGGGCCT 1051 CGCCGTCCAC GGCGATGAGC GTGAACGGAC GCAGCTCCGG AACGGGGATG 1101 TCGAGACCGT CGTCCACCCC CCGCCAGGCG GCGGGGGCGA GGTCGGGGTC 1151 CTTCACGAAC CGGGGATCGG CCAGCACCTC GCGGGCGAGG GCGTCATCGG 1201 TGATGACCCA GGCGGGTCCG CCCGCGGGGG CGTTCACCTC GACGACCGGG 1251 CCCGCCTCCC GGAAGGCGTC GTGCACCTCG GGCTTGCGCT GCATGGTCAT 1301 CATGGGACAC GCGAACGGGT CGACGGCCAC CCGGGGCGCC TCGCCGCTCA 1351 CGAGGCACCG CCGCCGCCG CGGGGTACCC CTCCCGCAGT TCGACCACCG 1401 AGAAGCCGGC CCCGTGCGGG TCGAGCAGGT CCGCCGCCG CCCCCTGGGC 1451 GTGTCGGCGG GCTCGTTCTC GACGGAGCCG CCGAGTTCAA CGGCGCCCG 1501 GACCGTCGCG TCGCAGTCGT GCACGGCGAA CAGCACGGCC CAGTGCGGCC 1551 GTACCGCGCC GGTGACGCCC AGCTCCTGGG TGCCGGCGAC CGGTGTGTCA 1601 CCGATGTGCC AGACCGGGTC GGTGACGCCC TTCAGTCCGG TGTCGGCCGG 1651 AGCCAGGCCG AGGGTCGCCG GGTAGAAGTC CCGGGCGGCC CCGATGCCGT

10

15

20

25

30

35

40

50

1701 CGGTCACCAG CTCGACCCAG CCGACCGAGC CGGGCACGCC CGTCACCTCC 1751 GCGCCCTCCA TGACTCCCTT GCGCCAGACC GCGAACGCGG CCCCGGCGGG 1801 GTCGGCGAAG ACCGCCATCC GGCCGAGGCC GAGGACGTCC ATCGGAGTCA 1851 TGATGACCTC GCCGCCCGCC GTCTCGACCC GCTTGGTCAG TGCGTCGGCG 1901 TCGTCGGTGG CGAAGTACAC GGTCCAGATG GCCGGCATGC CGTGCTGGTC 1951 GTTCCCGGGC CCGTACGGCC GGTGGTAGGG GGTGTCGATC TGGTGGCGGG 2001 CGACCGCGC GACCAGCTTC CCGTCGGAGC TGAACGTCGT GTATCCCCCG 2051 GCGCCGGGT CGCTGACCAC GGTGGCGGTC CAGCCGAACA GGCCGGTGTA 2101 GAAGTCGGCC GAGGCGGCGA CATCGGGCGA ACCGAGGTCG AACCATGCGG 2151 GGGCGCCGGG CGCGAACCTG GTCACGAATC GTTCCTTTCG ATGGATCGGC 2201 ACACGAGCGT CTGCGCTCGC GGATGAGACG GACATCTCGC GGATGAGACG 2251 GACATGCGGG CGGGGGGGC CGCCGCCGTC AGTGCGCGGT GTCGCCGACG 2301 GCGGCCGCG CGGCCTCCCA GAGCTTCGCC GCGAGGCCGG CGTCGGCGGT 2351 CGGGCCGCTC ACCGGGGACA GCCGCCGGTC GCTGTAGTAG CCGCCCGTGG 2401 TCAACTCCTC GGCCGCCGCG GACGCCAGCC ACACGAGGGT GTCGGCGCCC 2451 TTCGCCGCGG AGCGCAGGAA GGGGTTGAAC CGGAAGTAGG ACGAGGCGAC 2501 CGTGCCCGT CCGATGCGGG TGCGGACCTC ACCGGGGTGA TAGCTGACCG

2551 CCAGCACGTC CGGCCAGCGC CTGGCGGCCT CCGCCGCGGT CATGATGTTG

5 2601 GCCTGTTTGG ACGTGCCGTA CGCCTGGCCG GCGCTGTAGC GGTGACGGTC

2651 GCCGTTGAGG TCGTCCGGGT CGATCCGGCC CTGGGTGTAC GCGTCGGACG

2701 AGGTGAGGAT CAGCCGCCCG CCCGCGAGCC GCTCCCGCAG CAGCCGTGCC

2751 AGCAGGAAGC CTGCGAGGTG ATTGACCTGG ATGGTGGCCT CGAACCCGTC

2801 CTGGGTCGTG GTGCGCGACC AGAACATGCC GCCGGCGTTG CTGGCCATGA

20 2851 CATCGATGCG CGGGTACCGG

CLAIMS

- 1. A DNA molecule comprising a DNA region containing a gene *dox*A encoding daunorubicin 14-hydroxylase and a DNA region containing at least one gene conferring daunorubicin and doxorubicin resistance.
 - 2. A DNA molecule according to claim 1, further comprising a strong promoter.
 - 3. A DNA molecule according to claim 2, wherein said strong promoter is ermE*.
- 4. A DNA molecule according to claim 1, wherein said gene conferring daunorubicin and doxorubicin resistance is selected from the group consisting of *drr*A, *drr*B and *drr*C genes and any mixtures thereof.
- 5. A DNA molecule according to claim 4, wherein said genes conferring daunorubicin and doxorubicin resistance are *drr*A and *drr*B genes.
- 6. The DNA molecule according to claim 4, wherein said genes conferring daunorubicin and doxorubicin resistance are *drr*A, *drr*B and *drr*C genes.
- 7. The DNA molecule according to claim 1, wherein the region containing the gene *dox*A encoding daunorubicin 14-hydroxylase is 2.9 kb in length.
- 8. The DNA molecule according to claim 7, wherein the fragment containing the gene doxA corresponds to the *Kpnl-Bam*HI fragment containing the doxA nucleotide sequence.
 - 9. The DNA molecule according to claim 5, wherein said region containing said

drrA and drrB genes is a 2.3 kb Xbal-HindIII DNA fragment.

- 10. The DNA molecule according to claim 1, wherein said genes conferring daunorubicin and doxorubicin resistance are at least 80% identical to genes selected from the group consisting of *drr*A, *drr*B and *drr*C genes.
 - 11. A vector containing a DNA molecule according to claim 1.
 - 12. A vector according to claim 11 wherein said vector is a plasmid.
- 13. A plasmid according to claim 12, wherein said plasmid is selected from the group consisting of pIS284 and pIS287.
 - 14. A host cell transformed or transfected with a vector according to claim 11.
- 15. The host cell according to claim 14, wherein said host cell does not produce daunorubicin.
- 16. The host cell according to claim 14, wherein said host cell is a bacterial cell which produces daunorubicin.
- 17. The recombinant host cell according to claim 14, wherein said host cell is a Streptomyces cell.
- 18. A process for bioconverting daunorubicin into doxorubicin, comprising the steps of:
 - culturing a recombinant host cell in a culture medium containing daunorubicin, wherein said host cell contains a DNA molecule comprising a DNA

region containing a gene doxA encoding daunorubicin 14-hydroxylase and a DNA region containing at least one gene conferring daunorubicin and doxorubicin resistance, wherein said host cell does not produce daunorubicin, and

isolating any resulting doxorubicin from the culture medium.

19. A process for producing doxorubicin by fermentation, comprising the steps of: culturing a recombinant host cell in a culture medium, wherein said host cell contains a DNA molecule comprising a DNA region containing a gene doxA encoding daunorubicin 14-hydroxylase and a DNA region containing one or more genes conferring daunorubicin and doxorubicin resistance, wherein said host cell is a bacterial cell which produces daunorubicin, and


isolating any resulting doxorubicin from the culture medium.

WO 99/55829


SEQUENCE LISTING

```
<110> PHARMACIA & UPJOHN S.P.A.
   <120> PROCESS FOR PREPARING DOXORUBICIN
   <130> 1615-9003
   <140> PCT/UNKNOWN
   <141> 1999-04-22
   <150> 09/065.606
   <151> 1998-04-24
   <160> 1
   <170> PatentIn Ver. 2.0
   <210> 1
   <211> 2870
   <212> DNA
   <213> Streptomyces peucetius
   <220>
   <221> misc feature
   <222> Complement((1)..(2870))
   <223> Complementary strand to the coding strand
   <400> 1
   ggatccgcac cgggtacacg gcacgggacc gcccaccgcg cggtgcgcgg tgggcggtcc 60
   cqtqccqqtc qcqqccqqcq qatcaqcqca qccaqacqqq caqttcqqtq agccqcqccq 120
totgggoocc ottooggoac cacegoaact ogtogtacgg cacggocagt ogggootogg 180
ggaacetget gegeagtacg ecgateateg tgegegacte eagetgggeg agetgeteee 240
  cgatgcagta gtgcggcccg tcgccgaagg tgagccgccg ccacgaggga cggtccgggt 300
   ggaaggcgtg cggggcgtcg tgatggcggc cgtcggtgtt ggtgccctcg atgtccacca 360
   gcaccggcgc tccgcggggc agccggacgc cgccgatggt cacctccgtg gcagcgaacc 420
   tocacaacgt gragggcace ggegggtggt agegeagege etectecaeg aacegggaga 480
  cggcgtcctc gtcggcatcc gccgcgaggc ggcccgccag gacctccgcg agcaggaagc 540
   ccaggaagga gccggtggtg tcgtggccgg cgaagatgag cccggtgatc atgtagacga 600
   gctggtcgtc ggagaccgag ccgaactcgg cctgcgcgcg ctcgtacagc acgcgggtca 660
   tggtcggggt gtcgttccgc cgggctgagt gcacggcttc gaggagcagg ctctccaggg
   eegaggtgte eggeaegeee eeggeagggt eegtgeegte acceeegeeg etetgeggge 780
   egeegaggee gagtgeettg agaaegetga eggeetegeg ggeeategee ggateggtga 840
   coggoacaco gagoagotog cagatgacoa acagogggaa gtggtacgog aagoogooga 900
   teagetegge eggtttgeee gaceggeegg aggegtegge gagtteggtg ageageegge 960
   eggegatege ggegatgega teegteeget eggeeageeg gegegggttg aacgeaggtg 1020
   cgtggatgcg gcgcaggcgc cggtgggcct cgccgtccac ggcgatgagc gtgaacggac 1080
   geageteegg aaeggggatg tegagaeegt egteeaeeee eegeeaggeg geggggega 1140
   ggtcggggtc cttcacgaac cggggatcgg ccagcacctc gcgggcgagg gcgtcatcgg 1200
   tgatgaccca ggcgggtccg cccgcggggg cgttcacctc gacgaccggg cccgcctccc 1260
   ggaaggegte gtgcaceteg ggettgeget geatggteat catgggacae gegaaegggt 1320
   cgacgccac ccggggcgcc tcgccgctca cgaggcaccg cccgccgccg cggggtaccc 1380
   etccegcagt tegaceaceg agaageegge ceegtgeggg tegageaggt cegeeegeeg 1440
   eccectggge gtgteggegg getegttete gaeggageeg eegagtteaa eggegegeeg 1500
   gaccgtcgcg tcgcagtcgt gcacggcgaa cagcacggcc cagtgcggcc gtaccgcgcc 1560
   ggtgacgccc agctcctggg tgccggcgac cggtgtgtca ccgatgtgcc agaccgggtc 1620
   ggtgacgccc ttcagtccgg tgtcggccgg agccaggccg agggtcgccg ggtagaagtc 1680
   ccgggcggcc ccgatgccgt cggtcaccag ctcgacccag ccgaccgagc cgggcacgcc 1740
   egteacetee gegeeeteea tgaeteeett gegeeagaee gegaaegegg eeceggeggg 1800
   gtcggcgaag accgccatcc ggccgaggcc gaggacgtcc atcggagtca tgatgacctc 1860
   geogeoegee gtetegacee gettggteag tgegteggeg tegteggtgg egaagtaeae 1920
   ggtccagatg gccggcatgc cgtgctggtc gttcccgggc ccgtacggcc ggtggtaggg 1980
```


ggtgtcgatc tggtggcggg cgaccgcggc gaccagcttc ccgtcggagc tgaacgtcgt 2040 gtatoccocg gogocogggt ogotgaccac ggtggoggto cagoogaaca ggcoggtgta 2100 gaagteggee gaggeggega categggega accgaggteg aaccatgegg gggegeeggg 2160 cgcgaacctg gtcacgaatc gttcctttcg atggatcggc acacgagcgt ctgcgctcgc 2220 ggatgagacg gacatetege ggatgagacg gacatgeggg eggggeggge egeegeegte 2280 agtgogeggt gtogoogacg goggoogogo oggootocca gagottogoo gogaggoogg 2340 cgtcggcggt cgggccgctc accggggaca gccgccggtc gctgtagtag ccgccgtgg 2400 tcaactcctc ggccggcgcg gacgccagcc acacgagggt gtcggcgccc ttcgccqcqq 2460 agcgcaggaa ggggttgaac cggaagtagg acgaggcgac cgtgccccgt ccgatgcggg 2520 tgcggacctc accggggtga tagctgaccg ccagcacgtc cggccagcgc ctggcggcct 2580 ccgccgcggt catgatgttg gcctgtttgg acgtgccgta cgcctggccg gcgctgtagc 2640 ggtgacggtc gccgttgagg tcgtccgggt cgatccggcc ctgggtgtac gcgtcggacg 2700 aggtgaggat cagccgcccg cccgcgagcc gctcccgcag cagccgtgcc agcaggaagc 2760 ctgcgaggtg attgacctgg atggtggcct cgaacccgtc ctgggtcgtg gtgcgcgacc 2820 agaacatgcc gccggcgttg ctggccatga catcgatgcg cgggtaccgg 2870



2/10



3/10







Fig. 2a


5/10 **pIJ4070** 3Kb p-ermE* amp drrB . **pIS278** 5.3Kb Xbal, HindIII lacZ drrA p-ermE* GETK BXB amp ori-E.coli drrA pdrrAB 5.3Kb drrB fl ori ambori-E.coli


Fig. 2b



The first car was truly and been belt. I said the first first first first form

8/10 pIJ4070 3Kb GETK BXSHPG ori-E.coli EcoRI, HindIII **pIS282** 6.6Kb dmCamp ori-E.coli pWHM264 6.6Kb drrC fl ori ori-E.coli





Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

(Insert Title) PROCESS FOR PREPARING DOXORUBICIN

the specification of which is attached hereto unless the following box is checked:

was filed on April 22, 1999 as PCT International Application Number PCT/US99/07016 and was amended on

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.

1 hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §36∮(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application(s) for which priority is claimed: Descript Claimed

			!	Filling Claimed
	09/065,606	US	24 April 1998	
(List prior	(Number)	(Country)	(Day/Month/Year Filed)	
foreign applications.				🗆 Yes 🔲 No
See потс A	(Number)	(Country)	(Day/Month/Year Filed)	5 Y - 5 Y
on back of			(D) (M) (D) (T) (M)	□ Yes □ No
this page)	(Number)	(Country)	(Day/Month/Year Filed)	
	(Application Number)	(Filing	(Date)	
	(Application Number)	(Filing	Date)	
(See Note B on back			foreign or provisional applications.	
of this page)	□ See attached	list for additional prior	toteign of provisional appreciations.	

the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(List prior U.S. Applications or PCT International applications designating the U.S.)	(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
	(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

And I hereby appoint as principal attorneys: Robert B. Murray, Reg. No. 22,980; David T. Nikaido, Reg. No. 22,663; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; Monica Chin Kitts, Reg. No. 36,105; Richard J. Berman, Reg. No. 39,107; King L. Wong, Reg. No. 37,500; James A. Poulos, III, Reg. No. 31,714; Murat Ozgu, Reg. No. 44,275; Bradley D. Goldizen, Reg. No. 43,637; N. Alexander Nolte, Reg. No. 45,689; Robert K. Carpenter, Reg. No. 34,794; Gregory B. Kang, Reg. No. 45,273; Rustan I. Hill, Reg. No. 37,351; Rhonda L. Barton, Reg. No. P47,271; Carl Schaukowitch, Reg. No. 29,211; and Kevin F. Turner, Reg. No. 43,437.

Please direct all communications to the following address:

Arent Fox Kintner Plotkin & Kahn PLLC 1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036-5339

Telephone (202) \$57-6000; Telefax (202) 857-6395

I hereby declare that all statements made herein of my own knowledge are time and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

,	ı
M	
W	,

100

-

ŝ ļ.

See Note C on back of this page)

Full name of sole or first inventor: Augusto Inventi SOLARI

October 18, 2000 Date

Residence: Via Cascina Bianon, 17/2, I-20142 Milan, Italy

Citizenship: Italy

Post Office Address: Same as above

Rev. #15 1/14/00

	Full name of second joint inventor, if any: Giovanna ZANUSO	Oataban 18 2000
J.	Inventor's signature from the Centre	October 18, 2000
	Residence: Via Zoja Luigi, 5, I-20100 Milan, Italy	Date
1	Citizenship: Italy	
	Post Office Address; Same as above	
		•
	The second of th	
CAS	Full name of third joint inventor, if any: Silvia FILIPPINI Inventor's signature Silvia Filippini	October 18, 2000
3		October 18, 2000
l i	Residence: Via Elba, 30, I-20144 Milan, Italy	
	Citizenship: Italy	
į	Post Office Address: Same as above	
1		
ULL	Full name of fourth joint inventor, if any: Francesco TORTI	0 tober 10 2000
14	Inventor's signature Suous Cosco (Ott.	October 18, 2000
	Residence: Corso Garibaldi, 70, I-20121 Milan, Italy	
	Citizenship: Italy	
İ	Post Office Address: Same as above	
!		
1	Full name of fifth joint inventor, if any: Sharee OTTEN	
CN	Inventor's signature	Date
>	Residence: 5706 Nutone Street, Madison, WI 53711, U.S.A.	
	Citizenship: America (1317)	
	Post Office Address: Same as above	
<u> </u>	Full name of sixth joint inventor, if any: Anna Luisa COLOMBO	October 18, 2000
, N	Inventor's signature Analy a Colorla	Date Date
# r ./M	Residence: Via Elba, 14, I-20144 Milan, Italy	Date
ĒΛ, Ι	Citizenship: Italy	
ei Fi	Post Office Address: Same as above	
1 1257 1 1257 1 1257	Full name of seventh joint inventor, if any: Charles R. HUTCHINSON	
	Inventor's signature	Data
	Residence: 4293 South Deer Run Court, Cross Plains, WI 53528, U.S.A.	Date
	Citizenship: America	
	Post Office Address: Same as above	

Full name of second joint inventor, if any: Giovanna ZANUSO Inventor's signature	
Residence: Via Zoja Luigi, 5, I-20100 Milan, Italy	Date
Citizenship: Italy	
Post Office Address: Same as above	
Full name of third joint inventor, if any: Silvia FILIPPINI	
Inventor's signature	
Residence: Via Elba, 30, I-20144 Milan, Italy	Date
Citizenship: Italy	
Post Office Address: Same as above	
Full name of fourth joint inventor, if any: Francesca TORTI	
Inventor's signature	
Residence: Corso Garibaldi, 70, I-20121 Milan, Italy	Date
Citizenship: Italy	
Post Office Address: Same as above	
Full name of fifth joint inventor, if any: Sharee OTTEN	11/10/
Inventor's signature Sharel Utten	////6/00 Date
Residence: 5706 Nutone Street, Madison, WI 53711, U.S.A.	7 Date
Citizenship: America	
Post Office Address: Same as above	
Full name of sixth joint inventor, if any: Anna Luisa COLOMBO	
Inventor's signature	
Residence: Via Elba, 14, I-20144 Milan, Italy	Date
Citizenship: Italy	
Post Office Address: Same as above	
Full name of seventh joint inventor, if any Charles R. HUTCHINSON	/ ,
Inventor's signature	11/17/10
Residence: 4293 South Deer Run Court, Cross Plains, WI 53528, U.S.A.	D ate

Citizenship: America

Post Office Address: Same as above

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled (Insert Title) PROCESS FOR PREPARING DOXORUBICIN

the specification of which is attached hereto unless the following box is checked:

	on April 22, 1999 as PCT Internatio	onal Application Nu	umber PCT/US99/07016 and was amen	ided on
by any amendment if I acknowledge the d I hereby claim foreign certificate, or §365(a below and have also	eferred to above. ty to disclose information which is priority benefits under 35 U.S.C a) of any PCT International application	s material to patent . §119(a)-(d) or §30 tion which designatication for patent of	identified specification, including the classifier ability as defined in 37 C.F.R. §1.56. 55(b) of any foreign application(s) for ped at least one country other than the Upper inventor's certificate or PCT International	atent or inventor's
	09/065,606	US	24 April 1998	Priority Claimed
(List prior foreign	(Number)	(Country)	(Day/Month/Year Filed)	- 100 E 110
applications. See note A	(Number)	(Country)	(Day/Month/Year Filed)	☐ Yes ☐ No
on back of this page)	(Number)	(Country)	(Day/Month/Year Filed)	□ Yes □ No
I hereby claim the b	enefit under 35 U.S.C. §119(e) of a		rovisional application(s) listed below. 2 Date)	
	(Application Number)	(Filing	g Date)	
(See Note B on back of this page)	☐ See attached list f	or additional prior	foreign or provisional applications.	
designating the Unite disclosed in the prior the duty to disclose i	ed States of America listed below ar rapplication(s) (U.S. or PCT) in the	id, insofar as the su e manner provided entability as define	ation(s) or §365(c) of any PCT Internation bject matter of each of the claims of thin by the first paragraph of 35, U.S.C. §1 in 37 C.F.R. §1.56 which became availing date of this application.	s application is not 12, I acknowledge
(List prior U.S.		_		
Applications or PCT International applications	(Application Serial No.)	(Filing Date	(Status) (patented, per	nding, abandoned)
designating the U.S.)	(Application Serial No.)	(Filing Date)	(Status) (patented, per	nding, abandoned)
Marmelstein, Reg. N Reg. No. 36,105; R Murat Ozgu, Reg. N Reg. No. 34,794; G	No. <u>25,895;</u> George E. Oram, Jr., R ichard J. Berman, Reg. No. 39,107 To. 44,275; Bradley D. Goldizen, Ro	eg. No. 27,931; Do ; King L. Wong, F eg. No. 43,637; N. Rustan J. Hill, Reg	22,980; David T. Nikaido, Reg. No. 22,0980; David T. Nikaido, Reg. No. 33,125; No. 37,500; James A. Poulos, III, Alexander Nolte, Reg. No. 45,689; Ro. No. 37,351; Rhonda L. Barton, Reg. No. 10,000;	Monica Chin Kitts, Reg. No. 31,714; bert K. Carpenter,
Please direct all com	nmunications to the following addre	1050 Connec Washington,	intner Plotkin & Kahn PLLC ticut Avenue, N.W., Suite 600 D.C. 20036-5339 02) 857-6000; Telefax (202) 857-6395	
are believed to be tri	ie; and further, that these statement	ts were made with	rue and that all statements made on infe	ermation and belief ents and the like so

y fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

See Note C n back of	Full name of sole or first inventor: Augusto Inventi SOLARI	
his page)	Inventor's signature	
	Residence: Via Cascina Bianca, 17/2, I-20142 Milan, Italy	Date
	Citizenship: Italy	
	Post Office Address: Same as above	